Platelet serotonin in combat related posttraumatic stress disorder with psychotic symptoms

Pivac, Nela; Kozarić-Kovačić, Dragica; Mustapić, Maja; Deželjin, Martina; Borovečki, Andreja; Grubišić-Ilić, Mirjana; Muck-Šeler, Dorotea

Source / Izvornik: **Journal of Affective Disorders, 2006, 91, 223 - 227**

Journal article, Accepted version
Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

https://doi.org/10.1016/j.jad.2006.02.018

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:472782

Pivac, N., Kozarić-Kovačić, D., Mustapić, M., Dezeljin, M., Borovečki, A., Grubišić-Ilić, M., Muck-Šeler, D. (2006) *Platelet serotonin in combat related posttraumatic stress disorder with psychotic symptoms.* Journal of Affective Disorders, 91 (1-3). pp. 223-227.

http://www.sciencedirect.com/science/journal/01650327

Brief report

Platelet serotonin in combat related posttraumatic stress disorder with psychotic symptoms

Nela Pivac[a*], Dragica Kozaric-Kovacic[b], Maja Mustapic[a], Martina Deželjin[a], Andreja Borovecki[b], Mirjana Grubišic-Ilić[b], Dorotea Muck-Seler[a]

[a]Rudjer Boškovic Institute, POBox 180, HR-10002 Zagreb, Croatia,
[b]University Hospital Dubrava, Referral Centre for the Stress-Related Disorders, Avenija Gojka Šuška 6, HR-10000 Zagreb, Croatia

Short Title: Platelet 5-HT and psychotic PTSD

*Corresponding author: Division of Molecular Medicine, Ruđer Bošković Institute, POBox 180, HR-10002 Zagreb, Croatia, Tel: +385 1 4571 207; Fax: + 385 1 4561-010;
E-mail address: npivac@.irb.hr (Nela Pivac)

Key words: combat related posttraumatic stress disorder, psychotic symptoms, platelet serotonin, war veterans

Abstract

Background: Combat-related posttraumatic stress disorder (PTSD) is severe form of PTSD, frequently associated with psychotic symptoms. Platelet serotonin (5-hydroxytryptamine, 5-HT) was used as a peripheral 5-HT marker to identify particular symptoms in PTSD.

Methods: Platelet 5-HT was determined fluorimetrically in 67 war veterans with combat related PTSD, 36 combat exposed veterans who did not develop PTSD, 35 veterans with PTSD complicated with psychotic features. PTSD diagnosis of current and chronic PTSD, and clinical symptoms of PTSD and psychoses were assessed according to DSM-IV criteria, using the Clinician Administrated PTSD Scale, and Positive and Negative Syndrome Scale (PANSS).

Results: Platelet 5-HT concentration was significantly higher in veterans with psychotic PTSD than in veterans with non-psychotic PTSD, veterans without PTSD, or in control subjects. Platelet 5-HT was significantly positively correlated with the positive symptoms in PANSS subscale, and with the symptoms of delusions within PANSS positive subscale.

Limitations: The results were obtained on peripheral 5-HT marker, i.e. platelet 5-HT concentration.

Conclusions: Since the delusions are the core psychotic symptoms occurring in our psychotic PTSD patients, the result of the increased platelet 5-HT concentration, associated with delusions, indicate that platelet 5-HT might be used as a trait marker of psychotic symptoms in PTSD, but not as a state marker for PTSD.

1. Introduction

Posttraumatic stress disorder (PTSD) occurs after an extreme, life threatening traumatic event. Combat-related PTSD is a severe form of PTSD, sometimes associated with psychotic symptoms (Hamner, 1997; Hamner et al., 1999). The underlying neurobiological dysfunction of PTSD includes the abnormalities in different neurotransmitter and neuroendocrine systems (Morgan III et al., 2003). Serotonin (5-hydroxytryptamine, 5-HT) is implicated in the pathophysiology of PTSD, since 5-HT alterations might contribute to the cognitive disturbances in PTSD (van Praag, 2004) and aggression (Goveas et al., 2004), 5-HT drugs (sertraline) show clinical efficacy of in the treatment of PTSD (Brady et al., 2000), and administration of the 5-HT_2 agonist meta-chlorophenylpiperazine provokes PTSD symptoms (Southwick et al., 1997).

Blood platelets share similarities (receptors, transporter, uptake, storage and release of 5-HT) with the central 5-HT synaptosomes (Camacho and Dimsdale, 2000; Stahl, 1985), and platelet 5-HT has been associated with depressive symptoms in PTSD (Muck-Seler et al., 2003), and aggression (Goveas et al., 2004). Since biological markers are associated to single psychological dysfunction (Mueller-Oerlinghausen et al., 2004; van Praag, 2004), we hypothesized that platelet 5-HT concentration might be related with specific PTSD or psychotic symptoms in patients with combat related PTSD. The aim of the study was to evaluate the association between particular PTSD or psychotic symptoms, and platelet 5-HT concentration, in drug-free male war veterans with combat related PTSD, combat-exposed war veterans who did not develop PTSD, war veterans who had PTSD complicated with psychotic symptoms, and in healthy male control subjects.

2. Materials and methods

Participants were 39.4 ± 7.1 years old (range 24-56 years) male, drug-free war veterans (N=138) with chronic and current combat related PTSD, hospitalized at the Department of Psychiatry, University Hospital Dubrava, during 2001-2004 period. Diagnosis of chronic and current combat related PTSD was established using Structured Clinical Interview (SCID) based on DSM-IV criteria (APA, 1994). Groups were divided into 67 veterans with PTSD, 35 veterans with psychotic PTSD, and 36 veterans who did not develop PTSD. PTSD and psychotic symptoms were assessed with Clinician Administrated PTSD Scale (CAPS) (Weathers et al., 2001), and Positive and Negative Syndrome Scale (PANSS)

(Kay et al., 1987). Only patients with total Hamilton Rating Scale for Depression (HAMD) scores ≤ 18 (Hamilton, 1960) were included. The onset of PTSD in psychotic PTSD patients preceded the onset of psychosis. Psychotic symptoms (hallucinations or delusions on the psychotic module of the SCID, or specific disturbance in form of thoughts by mental status examination) and exclusion/inclusion criteria were described in our previous papers (Pivac et al., 2004a; Kozaric-Kovacic et al., 2005). The procedure was fully explained and written informed consent was obtained from all patients. Human ethics committee of the University Hospital Dubrava approved this protocol.

Control group consisted of 136 male drug-free healthy controls, mainly medical stuff, with no personal or family history of psychopathology, substance abuse or dependence, and no medical treatment. Veterans and healthy controls were sampled in the same period of the year.

Blood (4 ml) was drawn from cubical vein at 8.00 a.m. in a plastic syringe with 1 ml of acid citrate dextrose (ACD) anticoagulant. Platelet 5-HT concentrations were determined by the spectrofluorimetric method, as described before (Pivac et al., 2004b). Platelet protein was determined by the method of Lowry et al. (1951).

Statistical evaluation of the results, expressed as means ± SD, was done using one-way analysis of variance (ANOVA), followed by a Tukey's multiple comparison test, and correlations were determined by a Pearson's coefficient of correlation. The significance was accepted when $p<0.05$.

3. Results

The demographic data are presented in Table 1. Platelet 5-HT concentration differed significantly ($F(3,266)=3.387$, $p=0.019$), with significantly (Tukey's test) higher platelet 5-HT concentration in veterans with psychotic PTSD than in veterans with PTSD ($p=0.019$), without PTSD ($p=0.040$), or in control subjects ($p=0.029$). Platelet 5-HT concentration did not differ significantly ($p>0.05$) between control subjects, veterans with PTSD or veterans who did not develop PTSD (Fig. 1).

Age of the subjects (Table 1) differed significantly ($F(3,266)=10.839$, $p=0.000$), and control subjects (33.04 ± 11.24 years) were significantly (Tukey's test) younger than veterans with PTSD ($p=0.000$), without PTSD ($p=0.037$), or with psychotic PTSD ($p=0.019$).

No significant correlation was found between platelet 5-HT concentration and age in control subjects ($r=-0.013$; $p=0.909$), veterans with PTSD ($r=0.078$; $p=0.531$), without PTSD ($r=-0.023$; $p=0.896$), or with psychotic PTSD ($r=-0.222$; $p=0.208$).

Since platelet 5-HT was significantly increased in 35 psychotic PTSD patients, to find out the association between platelet 5-HT concentration and psychotic symptoms, a correlation between platelet 5-HT and the corresponding total and subscale scores in PANSS and CAPS was evaluated in these patients (Table 2). Platelet 5-HT concentration was significantly correlated with the scores in PANSS positive subscale. Scores in other subscales in the PANSS or CAPS were not significantly related to platelet 5-HT concentration. To find out which symptoms were related with the increased platelet 5-HT concentration, platelet 5-HT was correlated with each single item listed in PANSS positive subscale. Platelet 5-HT concentration was significantly correlated with the symptoms of delusions. Other symptoms were not significantly correlated with platelet 5-HT concentration (Table 2).

4. Discussion

Our results showed that platelet 5-HT concentration was increased in drug-free veterans with chronic and current combat related PTSD complicated with psychotic features, when compared to veterans with or without PTSD, or to control subjects. A positive correlation was found between platelet 5-HT and positive symptoms listed in PANSS subscale, and this correlation was due to the relationship between increased platelet 5-HT and delusions.

The highest platelet 5-HT concentration was found in psychotic PTSD patients with delusions. This finding agrees with the association between platelet 5-HT content and aggression (Goveas et al., 2004), impulsivity and violence (Askenazy et al., 2000), psychotic symptoms of depression (Muck-Seler et al., 1996a; Pivac et al., 1997a), delusions in dementia (Meszaros et al., 1998), positive (Pivac et al., 1997b) or paranoid (Muck-Seler et al., 1991) symptoms of schizophrenia, supporting the hypothesis that platelet 5-HT concentration is related to trait markers (Askenazy et al., 2000; Peirson et al., 1999), such as psychotic symptoms in PTSD (present study). Our data suggest that platelet 5-HT may distinguish between PTSD subjects with and without psychotic symptoms. In line with previous data (Maguire et al., 1998; Mellman and Kumar, 1994; Muck-Seler et al., 2003; Pivac et al., 2002), our veterans with or without combat related PTSD had similar platelet 5-HT concentration as control subjects or combat exposed veterans who did not develop PTSD, indicating that platelet 5-HT is not associated with diagnosis of PTSD (van Praag, 2004). Platelet 5-HT concentration might be affected by sex, age or seasonality. The effect of sex was excluded with the inclusion of only male subjects; the possible effect of age on platelet 5-HT content was

neglected as no significant relation between age and platelet 5-HT was found in healthy (Muck-Seler et al., 1996b; Pivac et al., 2001; Pivac et al., 2004b) or PTSD (present study) subjects, and the possible seasonal influence on platelet 5-HT parameters (Jakovljevic et al., 1997) was avoided since war veterans and healthy controls were sampled in the same season.

The lack of significant relationship between platelet 5-HT and other subscales of PANSS or CAPS indicates that only delusions were associated with increased values of platelet 5-HT. In support to our data no association was found between platelet 5-HT and CAPS scores in less severely ill patients without psychotic symptoms (Pivac et al., 2002), or between platelet 5-HT content and uptake and scores measuring PTSD, depressive and anxiety symptoms (Maguire et al., 1998; Mellman and Kumar, 1994).

Although psychotic PTSD is not recognized as a separate entity, 30-40% of combat related PTSD patients develop psychotic symptoms, which add to a more severe form of PTSD (Butler et al., 1996; Hamner, 1997; Hamner et al., 1999; Mueser et al., 2002; Kozaric-Kovacic and Borovecki, 2005; Kozaric-Kovacic and Kocijan-Hercigonja, 2001; Kozaric-Kovacic et al., 2005; Pivac et al., 2004a). Psychotic features in our PTSD patients were not due to previous comorbidity, as we excluded patients with previous Axis I disorders. Increased concentration of cerebrospinal fluid corticotrophin releasing hormone (Sautter et al., 2003), decreased activity of the plasma dopamine beta hydoxylase (Hamner and Gould, 1998), and increased platelet 5-HT concentrations (present study) were found in psychotic PTSD, suggesting a biologically distinct psychotic PTSD subtype.

The limitation of the study was the use of peripheral marker, platelet 5-HT concentration. The advantage of the study was in the inclusion criteria of only drug-free war veterans with or without combat related PTSD, and/or psychotic symptoms, a large sample (N=138), and detailed clinical assessment with instrument measures such as SCID, CAPS and PANSS.

In conclusion, platelet 5-HT concentration was increased in war veterans with psychotic PTSD, and there was a significant relationship between psychotic symptoms, especially delusions, and platelet 5-HT concentration in these patients. The data suggest that platelet 5-HT concentration might be used as a trait marker for PTSD with psychotic features.

Acknowledgements

Thanks are due to the psychiatric personnel of the University Hospital Dubrava. This work was supported by Croatian Ministry of Science, grant number 0098088.



Figure 1: Platelet 5-HT concentration (mean ± SD) in war veterans with psychotic PTSD, war veterans with nonpsychotic PTSD, war veterans without PTSD, and in male healthy controls. Number of subjects is given in brackets. * $p < 0.05$ vs. platelet 5-HT concentration in war veterans with nonpsychotic PTSD, war veterans without PTSD or control subjects, Tukey's test.

Table 1. Demographic data in war veterans with nonpsychotic or psychotic PTSD, and in war veterans without PTSD. Data are expressed as mean ± SD. Number of subjects is given in brackets.

	War veterans (138)		
	With PTSD (102)		Without PTSD
	Nonpsychotic (67)	Psychotic (35)	(36)
Age (years)	40.7 ± 7.3	37.9 ± 8.0	37.7 ± 4.3
PANSS total	73.3 ± 15.5	101.6 ± 16.4	36.0 ± 1.5
PANSS positive	13.2 ± 3.8	23.3 ± 6.0	7.3 ± 0.5
PANSS negative	10.5 ± 4.2	15.5 ± 4.8	7.4 ± 0.5
PANSS gen. psychopathology	41.4 ± 8.1	52.6 ± 7.2	17.8 ± 0.8
PANSS supplementary items	8.3 ± 2.4	10.7 ± 1.7	3.4 ± 0.5
CAPS total	71.9 ± 4.3	98.3 ± 3.0	18.8 ± 11.5

Table 2. Pearson's coefficient of correlation (r) between platelet 5-HT and scores in clinical scales (total and subscale scores in PANSS and in CAPS) and symptoms in PANSS positive subscale in war veterans with psychotic PTSD.

Clinical scales	correlation (r)	p
CAPS total	-0.061	0.730
PANSS total	0.068	0.703
PANSS positive	0.379	0.027*
PANSS negative	-0.176	0.319
PANSS general psychopathology	-0.056	0.751
PANSS supplementary items	-0.007	0.967
Symptoms in PANSS positive subscale:		
-Delusion	0.448	0.008*
-Conceptual disorganization	0.303	0.081
-Hallucinatory behavior	0.312	0.073
-Excitement	0.076	0.671
-Grandiosity	0.115	0.519
-Suspicioness/persecution	0.180	0.309
-Hostility	0.161	0.364

References

American Psychiatric Association.,1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Press, Washington, DC.

Askenazy, F., Caci, H., Myquel, M., Darcourt, G., Lecrubier, Y., 2000. Relationship between impulsivity and platelet serotonin content in adolescents. Psychiatry Res. 94, 19-28.

Brady, K., Pearlstein, T., Asnis, G.M., Baker, D., Rothbaum, B., Sikes, C.R., Farfel, G.M., 2000. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA 283, 1837– 844.

Butler, R.W., Mueser, K.T., Sprock, J., Braff, D.L., 1996. Positive symptoms of psychosis in posttraumatic stress disorder. Biol. Psychatry 39, 839-844.

Camacho, A., Dimsdale, J.E., 2000. Platelets and psychiatry: lessons learned from old and new studies. Psychosom. Med. 62, 326-336.

Goveas, J.S., Csernansky, J.G., Coccaro, E.F., 2004. Platelet serotonin content correlates inversely with life history of aggression in personality-disordered subjects. Psychiatry Res. 126, 23-32.

Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 23, 56-62.

Hamner, M.B., 1997. Psychotic features and combat-associated PTSD. Depress. Anxiety 5, 34-38.

Hamner, M.B., Gould, P.B., 1998. Plasma dopamine beta-hydroxylase activity in psychotic and non-psychotic post-traumatic stress disorder. Psychiatry Res. 77, 175-181.

Hamner, M.B., Frueh, C., Ulmer, H.G,, Arana, G.W., 1999. Psychotic features and illness severity in combat related veterans with chronic posttraumatic stress disorder. Biol. Psychiatry 45, 846-852.

Jakovljevic, M., Muck-Seler, D., Pivac, N., Ljubicic, D., Bujas, M., Dodig, G., 1997. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biol. Psychiatry 41, 1028-1034.

Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull.13, 261-276.

Kozaric-Kovacic, D., Kocijan-Hercigonja, D., 2001. Assessment of posttraumatic stress disorder and comorbidity. Military Med. 166, 78-83.

Kozaric-Kovacic, D., Borovecki, A., 2005. Prevalence of psychotic comorbidity in combat related posttraumatic stress disorder. Military Med. 170, 223-226.

Kozaric-Kovacic, D., Pivac, N., Muck-Seler, D., Rothbaum, B.O., 2005. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J. Clin. Psychiatry 66, 922-927.

Lowry, O.H., Rosenbrough, N.S., Farr, A.C., Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-75.

Maguire, K., Norman, T., Burrows, G., Hopwood, M., Morris, P., 1998. Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry Res.77, 1-7.

Mellman, T.A., Kumar, A.M., 1994. Platelet serotonin measures in posttraumatic stress disorder. Psychiatry Res. 53, 99-101.

Meszaros, Z., Borsiczky, D., Mate, M., Tarcali, J., Szombathy, T., Tekes, K., Magyar, K., 1998. Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication and disease. Neurochem. Res. 23, 863-868.

Morgan III, C.A., Krystal, J.H., Southwick, S.M., 2003. Toward early pharmacological posttraumatic stress intervention. Biol. Psychiatry 53, 834-843.

Muck-Seler, D., Jakovljevic, M., Deanovic, Z., 1991. Platelet serotonin in subtypes of schizophrenia and unipolar depression. Psychiatry Res. 38, 105-113.

Muck-Seler, D., Jakovljevic, M., Pivac, N., 1996a. Platelet 5-HT concentrations and suicidal behavior in recurrent major depression. J. Affect. Disord. 39, 73-80.

Muck-Seler, D., Bujas, M., Ljubic-Thibal, V., Jakovljevic, M., 1996b. Effect of age on platelet 5-HT concentrations in healthy controls, depressed and schizophrenic patients. Neuropsychobiology 36, 19-21.

Muck-Seler, D., Pivac, N., Jakovljevic, M., Šagud, M., Mihaljevic-Peles, A., 2003. Platelet 5-HT concentration and comorbid depression in war veterans with or without posttraumatic stress disorder. J. Affect. Disord. 75, 171-179.

Mueller-Oerlinghausen, B., Roggenbach, J., Franke, L., 2004. Serotonergic platelet markers of suicidal behavior – do they really exist? J. Affect. Disord. 79, 13-24.

Mueser, K.T., Rosenberg, S.D., Goodman, L.A., Trumbetta, S.L., 2002. Trauma, PTSD, and the course of severe mental illness: an interactive model. Schizophrenia Res. 53,123-143.

Peirson, A.R., Heuchert, J.W., Thomala, L., Berk, M., Plein, H., Cloninger, C.R., 1999. Relationship between serotonin and the Temperament and character inventory. Psychiatry Res. 89, 29-37.

Pivac, N., Muck-Seler, D., Jakovljevic, M., Brzovic, Z., 1997a. Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Res. 73, 123-132.

Pivac, N., Muck-Seler, D., Jakovljevic, M., 1997b. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 36, 19-21.

Pivac, N., Muck-Seler, D., Barisic, I., Jakovljevic, M., Puretic, Z., 2001. Platelet serotonin concentration in dialysis patients with somatic symptoms of depression. Life Sci. 68, 2423-2433.

Pivac, N., Muck-Seler, D., Šagud, M., Jakovljevic, M., 2002. Platelet serotonergic markers in posttraumatic stress disorder. Progress Neuro-Psychopharmacol. Biol. Psychiatry 26, 1193-1198.

Pivac, N., Kozaric-Kovacic, D., Muck-Seler, D., 2004a. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related posttraumatic stress disorder. Psychopharmacology 175, 451-456.

Pivac, N., Muck-Seler, D., Mustapic, M., Nenadic-Šviglin, K., Kozaric-Kovacic, D., 2004b. Platelet serotonin concentration in alcoholic subjects. Life Sci. 76, 521-31.

Sautter, F.J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B., Myers, L., Johnson, J.E., Cerbone, A., Malaspina, D., 2003. Corticotrophin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol. Psychiatry 54, 1382-1388.

Southwick, S.M., Krystal, J.H., Bremner, D., Morgan, C.A.3rd, Nicolaou, A.L., Nagy, L.M., Johnson, D.R., Heninger, G.R., Charney, D.S., 1997. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 54, 749-758.

Stahl, S.M., 1985. Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons; in Longenecker GL (Ed): Platelets: Physiology and Pharmacology. New York, Academic Press, 1985, pp. 307-340.

van Praag, H.M., 2004. The cognitive paradox in posttraumatic stress disorder: a hypothesis. Progress Neuro-Psychopharmacol. Biol. Psychiatry 28, 923-935.

Weathers, F.W., Keane, T.M., Davidson, J.R.T., 2001. Clinician-administered PTSD scale: A review of the first ten years of research. Depress. Anxiety 13, 132-56.